Overview

Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension

Status:
NOT_YET_RECRUITING
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled clinical trial.
Phase:
NA
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Treatments:
ambrisentan